We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

201 hedge funds and large institutions have $1.92B invested in Portola Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 56 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 56

4% less funds holding

Funds holding: 209201 (-8)

17% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 36

20% less capital invested

Capital invested by funds: $2.41B → $1.92B (-$489M)

23% less call options, than puts

Call options by funds: $22.2M | Put options by funds: $28.9M

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

Holders
201
Holders Change
-8
Holders Change %
-3.83%
% of All Funds
4.37%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.13%
New
30
Increased
71
Reduced
56
Closed
36
Calls
$22.2M
Puts
$28.9M
Net Calls
-$6.72M
Net Calls Change
+$10.6M

PTLA Hedge Fund Activity: Q2 2019 in Review

201 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2019, worth a combined $1.92B — down 20% from $2.41B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of PTLA and 30 opened new positions — a net loss of 6 holders — while 56 trimmed existing stakes and 71 added.

The largest buyer was William Blair Investment Management, adding an estimated $26.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $90.8M sold.

  • 201 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2019, down from 209 in Q1 2019.
  • Funds reported $1.92B of Portola Pharmaceuticals, Inc. stock for Q2 2019, down 20% quarter-over-quarter.
  • 30 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2019 and 36 closed out, a net change of -6 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q2 2019 was William Blair Investment Management, an estimated $26.4M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q2 2019 was Deerfield Management, an estimated $90.8M sold.

Based on aggregated 13F filings for Q2 2019.